Study of 124I-NM404 in Advanced Solid Malignancies

• Status: Terminated
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: Cellectar Biosciences, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of advanced solid malignancy.

• Allowed tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head & neck cancer

• Disease must be at least 1cm in diameter

• Brain metastasis must be stable for at least one month.

• ECOG performance status 0-2

• Anticipated survival less than 5 years, as per the treating physician

Exclusion Criteria:

• Skin lesions only

• Chemotherapy or radiotherapy within 1 week

• Residual toxicities of grade 2 or greater from prior therapy

• Adequate organ function as per specified laboratory parameter

• Platelet count > or = to 75,000/uL